Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

8.7K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.7K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

3.1K
3.1K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

2.7K
2.7K
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

7.3K
Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome.  Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
7.3K
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

2.6K
2.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global to local burdens, inequalities, and achievable frontiers of child and adolescent malignant neoplasm of bone and articular cartilage across 953 countries and sublocations, 1980-2040, with deep learning-based forecasts.

Journal of orthopaedic translation·2026
Same author

Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial.

JAMA network open·2025
Same author

Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.

Cancers·2025
Same author

Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structures.

Annals of medicine·2025
Same author

Sinonasal Sarcomas Management: An International Consensus Statement.

International forum of allergy & rhinology·2025

Related Experiment Video

Updated: Feb 1, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

966

Advancing towards Better Cooperation for Better Sarcoma Prognoses.

Javier Martín Broto1

  • 1Department of Medical Oncology, HU Virgen del Rocio, Sevilla, Spain.

Oncology
|December 17, 2018
PubMed
Summary
This summary is machine-generated.

Multidisciplinary teams (MDTs) improve sarcoma care outcomes. International collaboration and mandatory MDTs are essential for advancing sarcoma treatment and research.

Keywords:
International collaborationMultidisciplinary teamsNational sarcoma networksSpanish Group for Research on Sarcomas

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.3K

Related Experiment Videos

Last Updated: Feb 1, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
09:38

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

966
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.3K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Multidisciplinary teams (MDTs) are crucial for optimal sarcoma patient care.
  • Evidence suggests improved outcomes for patients treated by MDTs or at specialized sarcoma centers.

Purpose of the Study:

  • To highlight the necessity of multidisciplinary expertise in sarcoma management.
  • To advocate for mandatory multidisciplinary teams and international cooperation in sarcoma research.

Main Methods:

  • Review of case/cohort studies on MDT treatment outcomes.
  • Analysis of the structure and benefits of national sarcoma networks and cooperative groups.
  • Case study of the Spanish Group for Research on Sarcomas (GEIS) expansion and collaboration.

Main Results:

  • MDTs and specialized centers are associated with better patient outcomes.
  • National networks and cooperative groups facilitate evidence-based guidelines and medical education.
  • Cooperative groups enhance patient accrual for rare cancers like sarcoma.

Conclusions:

  • Multidisciplinary team approach is essential for superior sarcoma care.
  • International collaboration among sarcoma groups is vital for addressing knowledge gaps.
  • Mandatory implementation of MDTs and international cooperation is recommended.